La sitagliptine dans le traitement du diabete de type 2: le point, cinq ans apres sa commercialisation. ; Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation
peer reviewed ; Sitagliptin (Januvia) was the first selective inhibitor of dipeptidyl peptidase-4 commercialized for the management of type 2 diabetes. It is also available as a fixed-dose combination with meformin (Janumet). Almost 5 years after its launch in Belgium, the present review summarizes the most recent data regarding the clinical efficacy of this antidiabetic agent, the controversy about its safety profile, its use at lower dosage in case of moderate to severe renal insufficiency, the various indications that have been successively accepted and reimbursed, and, finally, the perspec... Mehr ...